Loading...
XJPX4552
Market cap440mUSD
Jan 17, Last price  
548.00JPY
1D
-4.70%
1Q
-19.29%
Jan 2017
-23.11%
Name

JCR Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XJPX:4552 chart
P/E
12.49
P/S
1.60
EPS
43.88
Div Yield, %
3.64%
Shrs. gr., 5y
0.24%
Rev. gr., 5y
13.11%
Revenues
42.87b
+24.83%
8,099,740,0007,648,819,0008,544,735,00011,871,886,00012,082,718,00014,387,400,00014,457,846,00012,845,064,00014,099,910,00015,705,912,00016,855,654,00017,438,377,00018,085,035,00020,594,000,00023,160,000,00024,781,000,00030,085,000,00051,082,000,00034,343,000,00042,871,000,000
Net income
5.51b
+46.00%
-1,272,365,000-31,864,000-1,751,061,000399,972,000539,911,0001,302,874,000926,473,000633,989,000730,715,0001,296,206,0001,682,368,0001,789,474,0001,863,170,0003,070,000,0003,715,000,0002,678,000,0006,892,000,00014,507,000,0003,772,000,0005,507,000,000
CFO
9.31b
P
641,349,000746,573,0001,129,455,0001,923,514,0001,825,586,0002,357,537,000-18,331,000-421,110,0001,661,364,0004,565,361,000499,052,0002,201,746,0002,651,346,0003,133,000,0003,905,000,0004,927,000,00010,341,000,0009,289,000,000-5,500,000,0009,312,000,000
Dividend
Mar 28, 20250 JPY/sh

Profile

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
URL
https://www.jcrpharm.co.jp/
IPO date
Mar 16, 1995
Employees
879
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
42,871,000
24.83%
34,343,000
-32.77%
51,082,000
69.79%
Cost of revenue
22,854,000
17,688,000
17,636,000
Unusual Expense (Income)
NOPBT
20,017,000
16,655,000
33,446,000
NOPBT Margin
46.69%
48.50%
65.48%
Operating Taxes
1,707,000
1,625,000
4,886,000
Tax Rate
8.53%
9.76%
14.61%
NOPAT
18,310,000
15,030,000
28,560,000
Net income
5,507,000
46.00%
3,772,000
-74.00%
14,507,000
110.49%
Dividends
(2,500,000)
(2,739,000)
(2,169,000)
Dividend yield
2.32%
1.55%
0.77%
Proceeds from repurchase of equity
15,000
10,000
750,000
BB yield
-0.01%
-0.01%
-0.27%
Debt
Debt current
8,908,000
17,300,000
15,150,000
Long-term debt
14,432,000
5,646,000
2,994,000
Deferred revenue
(428,000)
(343,000)
Other long-term liabilities
1,267,000
1,190,000
1,044,000
Net debt
(4,536,000)
225,000
(15,602,000)
Cash flow
Cash from operating activities
9,312,000
(5,500,000)
9,289,000
CAPEX
(2,095,000)
(8,560,000)
(11,333,000)
Cash from investing activities
(2,690,000)
(15,002,000)
(3,250,000)
Cash from financing activities
(2,031,000)
1,948,000
(2,179,000)
FCF
13,825,000
1,267,000
20,750,000
Balance
Cash
18,756,000
13,278,000
30,977,000
Long term investments
9,120,000
9,443,000
2,769,000
Excess cash
25,732,450
21,003,850
31,191,900
Stockholders' equity
49,052,000
95,746,000
93,388,000
Invested Capital
55,308,550
51,119,150
32,780,100
ROIC
34.41%
35.83%
95.98%
ROCE
24.70%
22.96%
52.00%
EV
Common stock shares outstanding
125,397
124,838
124,209
Price
859.00
-39.21%
1,413.00
-37.39%
2,257.00
-37.04%
Market cap
107,716,071
-38.94%
176,396,549
-37.08%
280,340,207
-37.00%
EV
103,477,071
227,612,549
314,640,207
EBITDA
23,214,000
18,652,000
35,391,000
EV/EBITDA
4.46
12.20
8.89
Interest
86,000
44,000
45,000
Interest/NOPBT
0.43%
0.26%
0.13%